Study of MDX-010 in Patients With Metastatic Hormone-Refractory Prostate Cancer

NCT00323882 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

75

Enrollment

INDUSTRY

Sponsor class

Conditions

Prostate Cancer
Neoplasm Metastasis

Interventions

DRUG: MDX-010

Sponsor

Bristol-Myers Squibb